Senior safety medical evidence & insights lead
ZürichArgenx
...lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first‑in‑class neonatal Fc receptor blocker approved for the treatment of g MG, and with the potential to treat patients across dozens of severe [...]
Kategorie Handel